Related Experiment Video

Updated: Jun 27, 2025

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

65.3K

Beneficial Effects of PIN1 Inhibition on Diabetes Mellitus: A Concise Review

Meeramol C Chellappan1, Soumya Vasu1, Shriraam Mahadevan2

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, (DU) Porur-600 116, Chennai, India.

Endocrine, Metabolic & Immune Disorders Drug Targets
|May 2, 2024
PubMed

Insights

Type 2 diabetes mellitus (T2DM) management is challenging due to combinatorial therapy side effects. This review explores the protein interacting with NIMA (PIN1) enzyme as a potential therapeutic target for T2DM and related disorders.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Molecular Biology

Background:

  • Type 2 diabetes mellitus (T2DM) is a chronic condition requiring complex management, often involving combinatorial therapies with significant side effects like weight gain and hypoglycemia.
  • Current T2DM treatments face limitations due to short-lived effectiveness and adverse effects, necessitating novel therapeutic strategies.
  • The protein interacting with NIMA (PIN1) enzyme has emerged as a potential factor in T2DM pathogenesis and associated complications.

Purpose of the Study:

  • To review the existing literature on the role of PIN1 in the progression of T2DM.
  • To examine the correlation between PIN1 activity and diabetes-related disorders.
  • To explore the potential of PIN1 as a therapeutic target for T2DM management.

Main Methods:

  • Literature review of studies investigating PIN1's role in T2DM.
  • Analysis of research on PIN1 substrates and their involvement in metabolic pathways.
  • Examination of evidence linking PIN1 to diabetes-related complications.

Main Results:

  • PIN1 interacts with various substrates implicated in T2DM development and progression.
  • Evidence suggests PIN1 may influence insulin resistance and pancreatic beta-cell function.
  • PIN1 inhibition could offer a novel approach to managing T2DM and its comorbidities.

Conclusions:

  • PIN1 is a promising molecular target for T2DM therapy.
  • Targeting PIN1 may mitigate common side effects associated with current T2DM treatments.
  • Further research into PIN1 inhibition is warranted for developing effective T2DM regimens.
Keywords:
PIN1Type 2 DMdiabetesdiabetes mellitushypoglycemia.therapeutic target

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

405
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154